Evidence map›Paper›PMID 39612623›Full record

ArticleVirology2025

Distinct immune profiles in children living with HIV based on timing and duration of suppressive antiretroviral treatment.

Madeline J Lee, Morgan L Litchford, Elena Vendrame, Rosemary Vergara, Thanmayi Ranganath, Carolyn S Fish, Daisy Chebet, Agnes Langat, Caren Mburu, Jillian Neary and 5 more

Abstract read
In one paragraph

Article in Virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Madeline J LeeDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Stanford Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
Morgan L LitchfordDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Elena VendrameDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Rosemary VergaraDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Thanmayi RanganathDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Carolyn S FishDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Daisy ChebetDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Agnes LangatDivision of Global HIV & TB., Center for Global Health, U.S Centers for Disease Control and Prevention, USA.
Caren MburuDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Jillian NearyDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Sarah BenkiDepartment of Global Health, University of Washington, Seattle, WA, USA.
Dalton WamalwaDepartment of Pediatrics and Child Health, University of Nairobi, Nairobi, Kenya.
Grace John-StewartDepartment of Global Health, University of Washington, Seattle, WA, USA.
Dara A LehmanDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Catherine A BlishDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA. Electronic address: cblish@stanford.edu.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
Urgent Versus Post-Stabilization ART in HIV+ Children with Severe Co-infectionsR01HD023412 · NICHD · UNIVERSITY OF WASHINGTON · PI Grace C. John-Stewart, DALTON CHEKOKO WAMALWA · 1987 to 2026
$12.2M
Targeting natural killer cells to HIV in intravenous drug usersDP1DA046089 · NIDA · STANFORD UNIVERSITY · PI BLISH, CATHERINE A · 2018 to 2022
$3.9M
Infant immune mechanisms of HIV reservoir size and decayR01HD094718 · NICHD · UNIVERSITY OF WASHINGTON · PI JOHN-STEWART, GRACE C., LEHMAN, DARA ANN · 2017 to 2021
$3.6M
Defining the role of natural killer cells in COVID-19F31AI172319 · NIAID · STANFORD UNIVERSITY · PI LEE, MADELINE JANE · 2022 to 2024
$99k
NIAID NIH HHS F31 AI172319NIAID NIH HHS P30 AI027757NIAID NIH HHS T32 AI007290NICHD NIH HHS R01 HD023412NICHD NIH HHS R01 HD094718NIDA NIH HHS DP1 DA046089NIH HHS F31 AI172311-01NIH HHS T32 AI00729037
6 · The paper itself

Abstract

Timely initiation of antiretroviral therapy (ART) remains a major challenge in the effort to treat children living with HIV ("CLH") and little is known regarding the dynamics of immune normalization following ART in CLH with varying times to and durations of ART. Here, we leveraged two cohorts of virally-suppressed CLH from Nairobi, Kenya to examine differences in the peripheral immune systems between two cohorts of age-matched children (to control for immune changes with age): one group which initiated ART during early HIV infection and had been on ART for 5-6 years at evaluation (early, long-term treated; "ELT" cohort), and one group which initiated ART later and had been on ART for approximately 9 months at evaluation (delayed, short-term treated; "DST" cohort). We profiled PBMC and purified NK cells from these two cohorts by mass cytometry time-of-flight (CyTOF). Although both groups of CLH had undetectable viral RNA load at evaluation, there were marked differences in both immune composition and immune phenotype between the ELT cohort and the DST cohort. DST donors had reduced CD4 T cell percentages, decreased naive to effector memory T cell ratios, and markedly higher expression of stress-induced markers. Conversely, ELT donors had higher naive to effector memory T cell ratios, low expression of stress-induced markers, and increased expression of markers associated with an effective antiviral response and resolution of inflammation. Collectively, our results demonstrate key differences in the immune systems of virally-suppressed CLH with different ages at ART initiation and durations of treatment and provide further rationale for emphasizing early onset of ART.

Indexed as

HIV InfectionsViral LoadAdolescentAnti-HIV AgentsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCD4-Positive T-LymphocytesChildChild, PreschoolCohort StudiesFemaleHIV-1HumansKenyaKiller Cells, NaturalAnti-HIV AgentsAnti-Retroviral AgentsARTHIVImmunologyMonocytesNK cellsPediatric HIVT cells

Identifiers

PMID39612623
PMCPMC11645197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.